BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that, subject to market and other conditions, it intends to offer $200 million aggregate principal amount of its convertible senior notes due 2021 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Clovis Oncology also expects to grant the initial purchasers a 30-day option to purchase up to $30 million aggregate principal amount of additional notes on the same terms and conditions.
Help employers find you! Check out all the jobs and post your resume.
